Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery
09 mai 2024 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY Medtronic to fund...
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
08 mai 2024 16h05 HE
|
Vaxcyte, Inc.
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout,...
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
08 mai 2024 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
08 mai 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces interim data demonstrating no signs of disease progression in early-stage Stargardt patients treated with gildeuretinol.
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
08 mai 2024 09h00 HE
|
Turnstone Biologics Corp.
Dr. Sammy Farah, Turnstone's President and CEO, to present at the 2024 Bank of America Securities Health Care Conference in Las Vegas, NV.
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
08 mai 2024 09h00 HE
|
Therini Bio, Inc.
THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
08 mai 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
08 mai 2024 02h30 HE
|
Abivax
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST –...
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
07 mai 2024 16h00 HE
|
Abivax
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 Availability of the preparatory documents PARIS, France, May 7, 2024, 10:00PM CEST – Abivax SA (Euronext Paris & Nasdaq:...